

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1702)**

<b>In the Application of:</b>	)	
	)	
<b>Bachy <i>et al.</i></b>	)	
	)	<b>Examiner: Terra C. Gibbs</b>
<b>Serial No.: 09/980,265</b>	)	
	)	<b>Group Art Unit: 1635</b>
<b>Filing Date: March 22, 2002</b>	)	
	)	<b>Confirmation No.: 9818</b>
<b>For: Immunostimulant Oligonucleotide</b>	)	

**RESPONSE TO THE 37 CFR 1.105 REQUEST**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Please consider the following amendments and remarks made in response to the Office Action mailed March 9, 2006.

**Arguments/Remarks** begin on page 2 of this paper.

**ARGUMENTS/REMARKS**

In response to the request under 37 CFR 1.105, the applicants enclose herewith Figures 1-11 referred to in the application as filed. These figures were filed in the French priority application but were not included in the PCT application.

If the examiner believes a teleconference will advance prosecution, he is encouraged to contact the undersigned as indicated below.

Respectfully submitted,

Date: April 7, 2006

/Michael S. Greenfield/  
Michael S. Greenfield  
Registration No. 37,142

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive  
Chicago, IL 60606